Market cap data unavailable. We couldn't positively verify this ticker's market cap is under $500M. Verify independently before trading.
Nika Pharmaceuticals Inc.
- Market Cap
- Unavailable
- Price
- $0.51
- % Change (Daily % change from the live per-ticker quote feed.)
- +140.23%
- Volume
- 1.6K
About
Nika Pharmaceuticals Inc., a pharmaceutical enterprise headquartered in Henderson, Nevada, focuses on the creation of medications to address a broad spectrum of health conditions. Its research and development efforts target serious diseases including HIV/AIDS, hepatitis B and C, rheumatoid arthritis, cancer, and diabetes. The company's product line features antiviral treatments and nutritional supplements, notably providing a specialized thymus nuclear glycoprotein for the management of HIV. Originally established in 2000, the organization was previously known as Centennial Growth Equities Inc. before adopting its current name, Nika Pharmaceuticals, Inc., in May 2022.
Quick stats
Shares outstanding—
Computed float275.8M
Float / sharesUnknown
Key info
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001145604
AI Summary
AI-generated1/2
minorbullishoperations update
Nika Pharmaceuticals, Inc. (OTCQB: NIKA) Funding Update
Nika Pharmaceuticals is negotiating with investors from Thailand, Japan, Switzerland, Luxembourg, USA, Bulgaria, and the UAE for potential financing of up to $50 million.
CEO Dimitar Savov stated the company expects to make a final decision and finalize a funding deal by September 30 to secure capital for its investment program.
The company specializes in treating HIV/AIDS, Hepatitis B and C, and other diseases, with intellectual property covering six injectable drugs, four tablet drugs, and eleven dietary supplements.
Red flags
- Financing is subject to ongoing negotiation; no definitive agreement announced.
- Press release contains forward-looking statements regarding deal closure and production timeline.